Verona Pharma plc (NASDAQ:TARA) major shareholder Randall Marshall sold 2,516 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $26.42, for a total value of $66,472.72. Following the sale, the insider now owns 613,197 shares of the company’s stock, valued at $16,200,664.74. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Randall Marshall also recently made the following trade(s):

  • On Monday, July 27th, Randall Marshall sold 338 shares of Verona Pharma stock. The shares were sold at an average price of $26.08, for a total value of $8,815.04.
  • On Friday, July 24th, Randall Marshall sold 2,343 shares of Verona Pharma stock. The shares were sold at an average price of $26.53, for a total value of $62,159.79.
  • On Wednesday, July 22nd, Randall Marshall sold 1,372 shares of Verona Pharma stock. The shares were sold at an average price of $26.73, for a total value of $36,673.56.
  • On Friday, July 17th, Randall Marshall sold 1,601 shares of Verona Pharma stock. The shares were sold at an average price of $26.66, for a total value of $42,682.66.
  • On Monday, July 20th, Randall Marshall sold 4,330 shares of Verona Pharma stock. The shares were sold at an average price of $26.79, for a total value of $116,000.70.
  • On Monday, July 13th, Randall Marshall sold 2,145 shares of Verona Pharma stock. The shares were sold at an average price of $27.13, for a total value of $58,193.85.
  • On Friday, July 10th, Randall Marshall sold 2,659 shares of Verona Pharma stock. The shares were sold at an average price of $27.41, for a total value of $72,883.19.

Shares of Verona Pharma stock opened at $24.94 on Friday. Verona Pharma plc has a fifty-two week low of $8.80 and a fifty-two week high of $67.08. The stock has a 50 day simple moving average of $28.93.

Verona Pharma (NASDAQ:TARA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($1.40). As a group, analysts anticipate that Verona Pharma plc will post -2.59 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in TARA. Ikarian Capital LLC acquired a new position in Verona Pharma during the first quarter worth $10,368,000. DRW Securities LLC acquired a new position in Verona Pharma during the first quarter worth $3,071,000. Perceptive Advisors LLC acquired a new position in Verona Pharma during the first quarter worth $184,000. Citigroup Inc. acquired a new position in Verona Pharma during the first quarter worth $43,000. Finally, Victory Capital Management Inc. acquired a new position in Verona Pharma during the fourth quarter worth $32,000. Institutional investors own 67.70% of the company’s stock.

A number of equities research analysts have recently issued reports on TARA shares. Guggenheim assumed coverage on Verona Pharma in a research report on Wednesday. They issued a “buy” rating and a $50.00 price target for the company. Zacks Investment Research upgraded Verona Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, July 15th.

About Verona Pharma

ArTara Therapeutics, Inc develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.

See Also: What is a Special Dividend?

Insider Buying and Selling by Quarter for Verona Pharma (NASDAQ:TARA)

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.